G. Mathé, J. L. Amiel, L. Schwarzenberg, A. Cattan, and M. Schneider, Adoptive immunotherapy of acute leukemia: experimental and clinical results, Cancer Res, vol.25, pp.1525-1556, 1965.

M. M. Bortin, A compendium of reported human bone marrow transplants, Transplantation

J. Dausset,

, Acta Haematol, vol.20, pp.156-66, 1958.

R. Storb, R. F. Raff, F. R. Appelbaum, T. C. Graham, F. G. Schuening et al., Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts, Blood, vol.74, pp.1139-1182, 1989.

G. W. Santos and A. H. Owens, Allogeneic marrow transplants in cyclophosphamide treated mice, Transplant Proc, vol.1, pp.44-50, 1969.

G. W. Santos and P. J. Tutschka, Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia, J Natl Cancer Inst, vol.53, pp.1781-1786, 1974.

M. G. Inc, ESH -European School of Haematology

». Esh-ebmt, Handbook on Haematopoietic Stem Cell Transplantation, 2008.

S. Y. Choo, . The, and . System, Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patien, Yonsei Med J, vol.48, pp.11-23, 2007.

S. J. Lee, B. Logan, P. Westervelt, C. Cutler, A. Woolfrey et al., Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial, JAMA Oncol, vol.2, pp.1583-1592, 2016.

J. R. Passweg, H. Baldomero, P. Bader, C. Bonini, S. Cesaro et al., Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually, Bone Marrow Transplant, vol.51, pp.786-92, 2016.

H. Bonig, T. Papayannopoulou, G. Socié, R. A. Clift, D. Blaise et al., Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies, Leukemia, vol.27, pp.3569-74, 2001.

M. L. Sorror, M. B. Maris, B. Storer, B. M. Sandmaier, R. Diaconescu et al., Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities, Blood, vol.104, pp.961-969, 2004.

M. Mohty, O. Avinens, C. Faucher, P. Viens, D. Blaise et al., Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation, Haematologica, vol.92, pp.1004-1010, 2007.

. Ballen-kk, P. D. Colvin-g, and Q. Pj, Low Dose Total Body Irradiation Followed by Allogeneic Lymphocyte Infusion for Refractory Hematologic Malignancy-an Updated Review, Leuk Lymphoma, vol.45, pp.905-915, 2004.

B. Gyurkocza, R. Storb, B. E. Storer, T. R. Chauncey, T. Lange et al., Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, Khouri IF, vol.28, pp.2817-2841, 1998.

D. Blaise, R. Tabrizi, J. Boher, L. Corroller-soriano, A. Bay et al., Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigenmatched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation, Cancer, vol.119, pp.602-613, 2013.

R. Martino, S. Iacobelli, R. Brand, T. Jansen, A. Van-biezen et al., Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes, Blood, vol.108, pp.836-882, 2006.

M. Aoudjhane, M. Labopin, N. C. Gorin, A. Shimoni, T. Ruutu et al., , p.61

Y. Jm, . Jl, J. Finke, H. Shouten, D. Blaise et al., Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.19, pp.2304-2316, 2005.

A. Rambaldi, A. Grassi, A. Masciulli, C. Boschini, M. C. Micò et al., Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, The Lancet Oncology, vol.16, pp.1525-1561, 2015.

B. S. Andersson, M. De-lima, P. F. Thall, X. Wang, D. Couriel et al., National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant, vol.14, pp.945-56, 2005.

R. E. Billingham, The biology of graft-versus-host reactions, Harvey Lect, vol.62, pp.21-78, 1966.

N. A. Kernan, N. H. Collins, L. Juliano, T. Cartagena, B. Dupont et al., Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vhost disease, Blood, vol.68, pp.770-773, 1986.

N. A. Kernan, N. Flomenberg, B. Dupont, O. Reilly, and R. J. , Graft rejection in recipients of T-celldepleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes, Transplantation, vol.43, pp.842-849, 1987.

W. Krenger and G. A. Holländer, Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease, Best Pract Res Clin Haematol, vol.21, pp.4919-4946, 2008.

P. A. Rowlings, D. Przepiorka, J. P. Klein, R. P. Gale, J. R. Passweg et al., Cahn, vol.62

C. S. Jy, A. Gratwohl, G. Socié, M. M. Abecasis, K. A. Sobocinski et al., IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade, Br J Haematol, vol.97, pp.855-64, 1997.

J. Cahn, J. P. Klein, S. J. Lee, N. Milpied, D. Blaise et al., Prospective evaluation of 2 acute graftversus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study, Blood, vol.106, pp.1495-500, 2005.

J. Pidala, B. Kurland, X. Chai, N. Majhail, D. J. Weisdorf et al., Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium, Blood, vol.117, pp.4651-4658, 2011.

S. J. Lee, J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin et al., Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse, Blood, vol.100, pp.406-420, 2002.

N. K. Ramsay, J. H. Kersey, L. L. Robison, P. B. Mcglave, W. G. Woods et al., A randomized study of the prevention of acute graft-versus-host disease, N Engl J Med, vol.306, pp.392-399, 1982.

R. L. Powles, H. M. Clink, D. Spence, G. Morgenstern, J. G. Watson et al., Cyclosporin A to prevent graftversus-host disease in man after allogeneic bone-marrow transplantation, Lancet, vol.1, pp.327-336, 1980.

P. D. Ziakas, F. N. Zervou, I. M. Zacharioudakis, and E. Mylonakis, Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis, PLoS ONE, vol.9, p.114735, 2014.

T. Ruutu, A. Gratwohl, . Witte-t-de, B. Afanasyev, J. Apperley et al., Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice, Bone Marrow Transplantation, vol.49, pp.168-73, 2014.

J. Liu, J. D. Farmer, W. S. Lane, J. Friedman, I. Weissman et al., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes, Cell, vol.66, pp.807-822, 1991.

R. Storb, H. J. Deeg, J. Whitehead, F. Appelbaum, P. Beatty et al., Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N Engl J, vol.63

. Med, , vol.314, pp.729-764, 1986.

R. A. Nash, L. Johnston, P. Parker, J. S. Mccune, B. Storer et al., A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versushost disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, vol.11, pp.495-505, 2005.

V. Ratanatharathorn, R. A. Nash, D. Przepiorka, S. M. Devine, J. L. Klein et al., Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation, Blood, vol.92, pp.2303-2317, 1998.

A. C. Allison and E. M. Eugui, Mycophenolate mofetil and its mechanisms of action

, Immunopharmacology, vol.47, pp.85-118, 2000.

M. Kharfan-dabaja, R. Mhaskar, T. Reljic, J. Pidala, J. B. Perkins et al.,

, Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation, Cochrane Database Syst Rev, p.10280, 2014.

H. L. Lochte, A. S. Levy, D. M. Guenther, E. D. Thomas, and J. W. Ferrebee, Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate, Nature, vol.196, pp.1110-1111, 1962.

G. Socié, C. Schmoor, W. A. Bethge, H. D. Ottinger, M. Stelljes et al., Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius, Blood, vol.117, pp.6375-82, 2011.

J. Finke, W. A. Bethge, C. Schmoor, H. D. Ottinger, M. Stelljes et al., Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, vol.10, pp.70225-70231, 2009.

N. Kröger, C. Solano, C. Wolschke, G. Bandini, F. Patriarca et al., Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease, N Engl J Med, vol.374, pp.43-53, 2016.

R. Crocchiolo, B. Esterni, L. Castagna, S. Fürst, J. El-cheikh et al., First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, vol.18, pp.1150-63, 2012.

P. G. Beatty, R. A. Clift, E. M. Mickelson, B. B. Nisperos, N. Flournoy et al., Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings, New England Journal of Medicine, vol.313, pp.765-71, 1985.

R. L. Powles, G. R. Morgenstern, H. E. Kay, T. J. Mcelwain, H. M. Clink et al., Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J Clin Oncol, vol.1, pp.1767-77, 1983.

I. André-schmutz, L. Deist, F. Hacein-bey-abina, S. Vitetta, E. Schindler et al., Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study, Lancet, vol.360, pp.130-137, 2002.

E. C. Guinan, V. A. Boussiotis, D. Neuberg, L. L. Brennan, N. Hirano et al., Transplantation of anergic histoincompatible bone marrow allografts, N Engl J Med, vol.340, pp.1704-1718, 1999.

J. Peccatori, A. Forcina, D. Clerici, R. Crocchiolo, L. Vago et al., Sirolimus-based graftversus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors, Leukemia, vol.29, pp.396-405, 2015.

D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan et al., Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution, J Clin Oncol, vol.25, pp.690-697, 2007.

J. Bastien, J. Roy, and D. C. Roy, Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation, Semin Oncol, vol.39, pp.674-82, 2012.

Y. L. Kasamon, L. Luznik, M. S. Leffell, J. Kowalski, H. Tsai et al., Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome, Biol Blood Marrow Transplant, vol.16, pp.482-491, 2010.

F. Aversa, A. Tabilio, A. Velardi, I. Cunningham, A. Terenzi et al., Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype, N Engl J Med, vol.339, pp.1186-93, 1998.

F. Aversa, A. Terenzi, A. Tabilio, F. Falzetti, A. Carotti et al., Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse, J Clin Oncol, vol.23, pp.3447-54, 2005.

W. A. Bethge, C. Faul, M. Bornhäuser, G. Stuhler, D. W. Beelen et al., Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update, Blood Cells Mol Dis, vol.40, pp.13-22, 2008.

B. Federmann, M. Bornhauser, C. Meisner, L. Kordelas, D. W. Beelen et al., Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study, Haematologica, vol.97, pp.1523-1554, 2012.

F. Locatelli, P. Merli, D. Pagliara, L. Pira, G. Falco et al., Outcome of children with acute leukemia given HLA-haploidentical HSCT after ?? T-cell and B-cell depletion, Blood, vol.130, pp.677-85, 2017.

L. Kaynar, K. Demir, E. E. Turak, Ç. P. Öztürk, G. Zarars?z et al., TcR??-depleted haploidentical transplantation results in adult acute leukemia patients, Hematology, vol.22, pp.136-180, 2017.

D. Lu, L. Dong, T. Wu, X. Huang, M. Zhang et al., Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, vol.107, pp.3065-73, 2006.

D. Lu, L. Dong, T. Wu, X. Huang, M. Zhang et al., , p.67

Y. Xu, L. Zhang, Y. Ren, and H. , Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, vol.107, pp.3065-73, 2006.

H. X. Jun, C. Y. Jun, and Z. X. Yu, In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor, Haematologica, vol.89, pp.1517-1541, 2004.

X. J. Huang, Y. J. Chang, and X. Y. Zhao, Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions, Transpl Immunol, vol.17, pp.193-200, 2007.

Y. Wang, Y. Chang, L. Xu, K. Liu, D. Liu et al., Who is the best donor for a related HLA haplotypemismatched transplant?, Blood, vol.124, pp.843-50, 2014.

K. Lee, J. Lee, J. Lee, D. Kim, M. Seol et al., Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome, Blood, vol.118, pp.2609-2626, 2011.

D. Bartolomeo, P. Santarone, S. , D. Angelis, G. Picardi et al., Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies, Blood, vol.121, pp.849-57, 2013.

Y. Luo, H. Xiao, X. Lai, J. Shi, Y. Tan et al., T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT, Blood, vol.124, pp.2735-2778, 2014.

C. G. Brunstein, E. J. Fuchs, S. L. Carter, C. Karanes, L. J. Costa et al., Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLAmismatched related bone marrow or unrelated double umbilical cord blood grafts, Blood, vol.118, pp.282-290, 2011.

S. Piemontese, F. Ciceri, M. Labopin, W. Arcese, S. Kyrcz-krzemien et al., A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia, J Hematol Oncol, vol.10, p.24, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01501594

S. O. Ciurea, M. Zhang, A. A. Bacigalupo, A. Bashey, F. R. Appelbaum et al., Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood, vol.126, pp.1033-1073, 2015.

A. Bashey, X. Zhang, C. A. Sizemore, K. Manion, S. Brown et al., T-Cell?Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation, Journal of Clinical Oncology, vol.31, pp.1310-1316, 2013.

A. M. Raiola, A. Dominietto, A. Ghiso, D. Grazia, C. Lamparelli et al., Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning, Biol Blood Marrow Transplant, vol.19, pp.117-139, 2013.

S. R. Solomon, C. A. Sizemore, M. Sanacore, X. Zhang, S. Brown et al., Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial, Biol Blood Marrow Transplant, vol.18, pp.1859-66, 2012.

S. R. Solomon, C. A. Sizemore, M. Sanacore, X. Zhang, S. Brown et al., Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors, Biol Blood Marrow Transplant, vol.21, pp.1299-307, 2015.

E. J. Fuchs, Related haploidentical donors are a better choice than matched unrelated donors: Point, Blood Adv, vol.1, pp.397-400, 2017.

D. Blaise, S. Nguyen, J. O. Bay, P. Chevallier, N. Contentin et al., Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations

, Pathol Biol (Paris), vol.62, pp.180-184, 2014.

S. Nguyen, D. Blaise, J. O. Bay, P. Chevallier, N. Contentin et al., Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations

, Pathol Biol (Paris), vol.62, pp.185-194, 2014.

M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami et al., , p.69

M. Hamaguchi, T. Teshima, M. Tsuneyoshi, Y. Yoshikai, and S. Naito, Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor, Clin Cancer Res, vol.14, pp.2833-2873, 2008.

R. J. Jones, Haploidentical transplantation: repurposing cyclophosphamide, Biol Blood Marrow Transplant, vol.18, pp.1771-1773, 2012.

C. Pical-izard, R. Crocchiolo, S. Granjeaud, E. Kochbati, S. Just-landi et al., Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome, Biology of Blood and Marrow Transplantation, vol.21, pp.429-468, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01108575

A. Russo, G. Oliveira, S. Berglund, R. Greco, V. Gambacorta et al., NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications, Blood, vol.131, pp.247-62, 2018.

D. Niederwieser, H. Baldomero, J. Szer, M. Gratwohl, M. Aljurf et al., Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey, Bone Marrow Transplant, vol.51, pp.778-85, 2016.

J. R. Passweg, H. Baldomero, P. Bader, C. Bonini, R. F. Duarte et al., Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report, Bone Marrow Transplant, vol.52, pp.811-818, 2017.

A. Ruggeri, M. Labopin, G. Sanz, S. Piemontese, W. Arcese et al., Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia, Leukemia, vol.29, pp.1891-900, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02007180

C. Martínez, J. Gayoso, C. Canals, H. Finel, K. Peggs et al., Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, J Clin Oncol, vol.35, pp.3425-3457, 2017.

A. S. Kanate, A. Mussetti, M. A. Kharfan-dabaja, K. W. Ahn, A. Digilio et al., Reducedintensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors, Blood, vol.127, pp.938-985, 2016.

A. Rashidi, J. F. Dipersio, P. Westervelt, R. Vij, M. A. Schroeder et al., Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review, Biology of Blood and Marrow Transplantation, vol.22, pp.1696-701, 2016.

S. Garciaz, L. Castagna, R. Bouabdallah, S. Fürst, S. Bramanti et al., Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available, Bone marrow transplantation, vol.50, p.865, 2015.

S. R. Solomon, C. A. Sizemore, X. Zhang, S. Brown, H. K. Holland et al., Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia, Biol Blood Marrow Transplant, vol.22, pp.1816-1838, 2016.

A. M. Raiola, A. Dominietto, C. Di-grazia, T. Lamparelli, F. Gualandi et al., Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts, Biol Blood Marrow Transplant, vol.20, pp.1573-1582, 2014.

B. Yang, R. Yu, L. Cai, B. Guo, H. Chen et al., Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis, Bone Marrow Transplantation, p.1, 2018.

, ANNEXE 3 -NIH GLOBAL SCORE OF SEVERITY OF CHRONIC GVHD

S. Pavletic, S. Lee, G. Socie, and . Vgelsang, Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials, Bone Marrow Transplantation, 2006.

C. G. Kanakry, E. J. Fuchs, and L. Luznik, Modern approaches to HLA-haploidentical blood or marrow transplantation, Nature reviews Clinical oncology, p.75, 2016.

-. Annexe, Abréviation s : N=, effectif ; MO, moelle osseuse ; CSP, cellules souches périphériques ; HM, hémopathies malignes

. Lam,

. Mds, . Lnh, and . Lymphome-non-hodgkinien,

L. Lh and . De-hodgkin,

, RIC "reduced intensity conditioning

, MAC "myeloablative conditioning" ; GVHD "graft versus host disease

, All patients: incidence of GVHD according to donor group Cumulative incidence of aGVHD at day 100 (d100-aGVHD) was significantly higher in the UD group, NRM "non relapse mortality

B. ). , Among patients who received the RIC regimen, significant differences were observed comparing UD (n=80) vs. HRD (n=67) group: grade 2-4 d100-aGVHD 44% vs. 19%, p=0.008; grade 3-4 d100-aGVHD 14% vs. 3%, p=0.050; all-grade of 2y-cGVHD 27% vs. 16%, p=0.008; moderate or severe 2y-cGVHD 21% vs. 3%, p=0.002. Similar trends were observed in subgroups who received MAC regimens: UD (n=48) vs. HRD (n=14): grade 2-4 d100-aGVHD, p.36

, PBSCs: grade 3-4 d100-aGVHD: 0% vs. 3%, p=0.821; moderate or severe 2y-cGVHD: 0% vs 3%, p=0.383). Multivariate analysis confirmed a lower risk of GVHD

C. Nrm, O. S. Pfs, and L. Gragert, according to donor group No significant difference was observed in 2-years CIR (2y-CIR) between UD and HRD groups (24% vs. 14%, p=0.176, Table 2, Figure 2A), N. Engl. J. Med, vol.371, pp.339-348, 2014.

I. Yakoub-agha, Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen?Identical Siblings Versus Human Leukocyte Antigen?Allelic?Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy, Journal of Clinical Oncology, vol.24, pp.5695-5702, 2006.

R. F. Schlenk, Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A, Journal of Clinical Oncology, vol.28, pp.4642-4648, 2010.

S. J. Lee, High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, pp.4576-4583, 2007.

A. M. Raiola, Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts, Biology of Blood and Marrow Transplantation, vol.20, pp.1573-1579, 2014.

A. Bashey, T-Cell?Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation, Journal of Clinical Oncology, vol.31, pp.1310-1316, 2013.

L. Luznik, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol. Blood Marrow Transplant, vol.14, pp.641-650, 2008.

Y. L. Kasamon, Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults, J. Clin. Oncol, vol.33, pp.3152-3161, 2015.

R. Devillier, Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients, Br. J. Haematol, vol.176, pp.132-135, 2017.

D. Blaise, Haploidentical T Cell?Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen?Matched Related or Unrelated Donor, Biology of Blood and Marrow Transplantation, vol.22, pp.119-124, 2016.

J. Finke, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, vol.10, pp.855-864, 2009.

I. Walker, Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, The Lancet Oncology, vol.17, pp.164-173, 2016.

S. R. Solomon, Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial, Biol. Blood Marrow Transplant, vol.18, pp.1859-1866, 2012.

A. M. Raiola, Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning, Biol. Blood Marrow Transplant, vol.19, pp.117-122, 2013.

L. Castagna, Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Posttransplantation Cyclophosphamide, Biology of Blood and Marrow Transplantation, vol.20, pp.724-729, 2014.

R. Devillier, A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor, Am. J. Hematol, vol.89, pp.83-87, 2014.

R. L. Prentice, The analysis of failure times in the presence of competing risks, Biometrics, vol.34, pp.541-554, 1978.

R. J. Gray, A class of K-sample tests for comparing the cumulative incidence of a competing risk, The Annals of statistics, pp.1141-1154, 1988.

H. Glucksberg, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors, Transplantation, vol.18, pp.295-304, 1974.

A. H. Filipovich, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol. Blood Marrow Transplant, vol.11, pp.945-956, 2005.

E. L. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.53, p.457, 1958.

S. G. Holtan, Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, vol.125, pp.1333-1338, 2015.

P. Armand, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, vol.123, pp.3664-3671, 2014.

D. Ho, K. Imai, G. King, and E. Stuart, Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference, Political Analysis, vol.15, pp.199-236, 2007.

L. M. Foeken, Monitoring the international use of unrelated donors for transplantation: the WMDA annual reports, Bone marrow transplantation, vol.45, pp.811-818, 2010.

J. R. Passweg, Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report, Bone Marrow Transplant, vol.52, pp.811-817, 2017.

R. Devillier, HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison, Biol. Blood Marrow Transplant, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143551

J. Sugita, HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning, Biology of Blood and Marrow Transplantation, vol.21, pp.1646-1652, 2015.

K. Raj, Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity Conditioning, Biology of Blood and Marrow Transplantation, vol.20, pp.890-895, 2014.

S. O. Ciurea, Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant, vol.18, pp.1835-1844, 2012.

S. O. Ciurea, Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia, Blood blood, p.2015, 2015.

S. R. Solomon, Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors, Biology of Blood and Marrow Transplantation, vol.21, pp.1299-1307, 2015.

D. Stasi and A. , Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen?Matched Unrelated and Related Donors, Biology of Blood and Marrow Transplantation, vol.20, pp.1975-1981, 2014.

S. Piemontese, A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia, J Hematol Oncol, vol.10, p.24, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01501594

Y. Luo, T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT, Blood, vol.124, pp.2735-2743, 2014.

M. Baker, Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies, Biol. Blood Marrow Transplant, vol.22, pp.2047-2055, 2016.

B. Bolwell, A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation, Bone Marrow Transplant, vol.34, pp.621-625, 2004.

R. A. Nash, A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation, Biol. Blood Marrow Transplant, vol.11, pp.495-505, 2005.

R. Storb, Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia, New England Journal of Medicine, vol.314, pp.729-735, 1986.

P. Zikos, Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate, Blood, vol.91, pp.3503-3508, 1998.

C. G. Kanakry, Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning, J. Clin. Oncol, vol.32, pp.3497-3505, 2014.

C. G. Kanakry, Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide, Blood, vol.129, pp.1389-1393, 2017.

R. P. Gale and E. J. Fuchs, Is there really a specific graft-versus-leukaemia effect?, Bone Marrow Transplantation, vol.51, pp.1413-1415, 2016.

A. S. Kanate, Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors, Blood, vol.127, pp.938-947, 2016.

C. Martínez, Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, JCO, vol.35, pp.3425-3432, 2017.

A. Bashey, Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide, J. Clin. Oncol, vol.35, pp.3002-3009, 2017.

M. Debals-gonthier, Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years, Bone Marrow Transplant, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01868751

, Les incidences cumulées à 2 ans de maladie aigüe du greffon contre l'hôte (GVHD) de grade 3-4 (17% vs 2%, p = 0,003) et de GVHD chroniques modérées et sévères (20% vs 2%, p <0,001) étaient significativement plus élevées dans le groupe UD. La survie sans progression (PFS) était significativement meilleure dans le groupe HRD (51% vs 69%, p=0,019), RESUME La greffe allogénique de cellules souches hématopoïétiques (allo-CSH) est limitée par la disponibilité d'un donneur HLA identique apparenté (MSD). L'utilisation alternative de donneurs non apparentés (UD) est actuellement contestée par le recours à des donneurs apparentés partiellement compatibles dit haploidentiques (HRD)

, We retrospectively analyzed 209 consecutive patients younger than 60 years undergoing allo-HSCT from UDs (n=128) or HRDs (n=81)

, 003) and 2-year moderate and severe chronic (20% vs. 2%, p < 0.001) GVHD were significantly higher with UD. Progression free survival (PFS) was significantly better with HRD (51% vs. 69%, p = 0.019), without significant difference in the cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and overall survival (OS). Multivariate analyses confirmed the lower risk of acute and chronic GVHD

, better PFS (HR = 0.56, p = 0.015) and GRFS (HR = 0.43, p < 0.001) with HRD. This was confirmed in match-paired analysis, the absence of MSDs, HRD could be considered as a suitable alternative for patients younger than 60 years Short title: HRD-SCT with PT-Cy vs UD-SCT with ATG for patients under, p.60